FeesSafety
Pluang+

Phathom reports $84.7M Q3 revenue, $0 copay for VOQUEZNA, and reaffirms 2026 revenue guidance.

Company Fundamentals
19 Nov 2026, 03:45 WIB
The Motley Fool Team
View Source
Bullish
Phathom reports $84.7M Q3 revenue, $0 copay for VOQUEZNA, and reaffirms 2026 revenue guidance.

Phathom Pharmaceuticals reported third-quarter net revenues of $84.7 million, driven by strong sales of VOQUEZNA, its treatment for GERD. The company introduced a $0 copay program through BlinkRx for commercially insured patients to boost access and prescriptions. Phathom achieved positive operating profit and cash flow for two consecutive quarters, signaling financial strength. Management is defending VOQUEZNA's market exclusivity in court and reaffirmed full-year 2026 revenue guidance of $310 million to $325 million, expecting continued growth and profitability.

Phathom Pharmaceuticals is the story's subject, here is Pluang's Health-sector snapshot as of Nov 19, 2026 04:02 WIB: Out of 150 priced US health stocks, 49 rose and 100 fell. Notable movers include ALMS at USD 4.37 with a -9.81% change, SYRE at USD 101.41 up 8.10%, and TWST at USD 113.50 rising 8.05% with 69% sell and 31% buy order activity on Pluang.

More News

Nvidia posts triple-digit revenue growth but stock struggles amid leadership and regulatory concerns.

Nvidia posts triple-digit revenue growth but stock struggles amid leadership and regulatory concerns.

Nvidia reported exceptional third-quarter earnings with revenue and profits more than doubling year-over-year, driven by strong demand for its AI infrastructure. However, the stock price remains subdued due to uncertainty following founder Jensen Hua...

Company Fundamentals
Neutral
35 minutes ago
Target boosts store traffic 5.6% and food sales nearly 7% in Q3 2026 with tech-driven inventory upgrades.

Target boosts store traffic 5.6% and food sales nearly 7% in Q3 2026 with tech-driven inventory upgrades.

In Q3 2026, Target reported a 5.6% increase in comparable store sales and nearly 7% growth in food and beverage sales, driven by stronger customer visits and expanded automated inventory replenishment covering over 90% of products. Management is simp...

Company Fundamentals
Bullish
41 minutes ago
KBR's Q3 revenue rises 5% with record $5.8B tech backlog; plans Trinzic spin-off on Jan 4, 2027

KBR's Q3 revenue rises 5% with record $5.8B tech backlog; plans Trinzic spin-off on Jan 4, 2027

KBR reported a 5% revenue increase in Q3 2026 to $2.03 billion, driven by growth in its commercial technology business. The company's sustainable tech backlog hit a record $5.8 billion, up over 50% year-over-year, providing strong revenue visibility....

Company Fundamentals
Bullish
52 minutes ago
John B. Sanfilippo sees contract manufacturing growth offset retail losses amid industry shifts

John B. Sanfilippo sees contract manufacturing growth offset retail losses amid industry shifts

John B. Sanfilippo reported a 41.3% increase in contract manufacturing volume, offsetting declines in private brand retail sales due to changes in sourcing by key partners. The company is investing in high-speed production lines to expand private lab...

Company Fundamentals
Bullish
52 minutes ago
Alphabet's AI and cloud investments could double stock value by 2035 despite high spending risks.

Alphabet's AI and cloud investments could double stock value by 2035 despite high spending risks.

Alphabet continues to grow through its core Search, YouTube, and rapidly expanding Google Cloud businesses, with AI driving significant revenue growth. The company plans to spend around $200 billion on capital expenditures this year, more than double...

Market News
Bullish
52 minutes ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App